Long-term safety and tolerability of donepezil 23mg in patients with moderate to severe Alzheimers disease

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Tariot, Pierre ^a   Salloway, Steven ^b   Yardley, Jane ^c   MacKell, Joan ^d   Moline, Margaret ^e  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b BROWN UNIVERSITY   (United States)

^c EISAI CO LTD   (Japan)

^d PFIZER INC   (United States)

^e EISAI INC   (United States)

Author keywords

Clinical trial; Donepezil; Donepezil 23mg; Safety; Tolerability

Indexed keywords

DONEPEZIL; INDAN DERIVATIVE; NOOTROPIC AGENT; PHARMACOLOGICAL BIOMARKER; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; AMBULATORY CARE; ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMBULATORY CARE; BIOMARKERS, PHARMACOLOGICAL; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; TREATMENT OUTCOME;

EID: 84861922419     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-283     Document Type: Article

References (21)

1. Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Reisberg B, Burns A, Brodaty H, Eastwood R, Rossor M, Sartorius N, Winblad B, Int Psychogeriatr 1997 9 11 38 (Pubitemid 28045337)
2. DSM-IV. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders Arlington, VA: American Psychiatric Association Publishing Fourth 1995
3. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Neurology 2001 57 613 620 (Pubitemid 32782987)
4. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A, Lancet 2006 367 1057 1065
5. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ, Dement Geriatr Cogn Disord 2007 24 20 27 (Pubitemid 46985287)
6. Realistic expectations for treatment success in Alzheimer's disease. Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M, J Nutr Health Aging 2006 10 417 429 (Pubitemid 44845354)
7. Progressive cholinergic decline in Alzheimer's disease: consideration for treatment with donepezil 23mg in patients with moderate to severe symptomatology. Sabbagh M, Cummings J, BMC Neurol 2011 11 21
8. ARICEPT (donepezil hydrochloride) tablets and ARICEPT orally disintegrating tablets [package insert] NJ, Eisai Inc: Woodcliff Lake 2011
9. Effectiveness and tolerability of high-dose (23mg/d) versus standard-dose (10mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A, Clin Ther 2010 32 1234 1251
10. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 (Pubitemid 14076461)
11. Severe impairment battery. A neuropsychological test for severely demented patients. Panisset M, Roudier M, Saxton J, Boller F, Arch Neurol 1994 51 41 45 (Pubitemid 24020169)
12. Cornell Scale for depression in dementia. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA, Biol Psychiatry 1988 23 271 284 (Pubitemid 18047596)
13. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. White H, Pieper C, Schmader K, J Am Geriatr Soc 1998 46 1223 1227 (Pubitemid 28467424)
14. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI, Drugs Aging 2007 24 155 167 (Pubitemid 46327574)
15. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, Bahra R, Drugs Aging 2004 21 43 53 (Pubitemid 38186948)
16. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease. Relkin N, Reichman W, Orazem J, McRae T, Dement Geriatr Cogn Disord 2003 16 15 24 (Pubitemid 36469808)
17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E, J Am Geriatr Soc 2001 49 1590 1599 (Pubitemid 34007984)
18. Dementia-associated mortality at thirteen years in the NEDICES Cohort Study. Villarejo A, Benito-Leon J, Trincado R, Posada IJ, Puertas-Martin V, Boix R, Medrano MR, Bermejo-Pareja F, J Alzheimers Dis 2011 26 543 551
19. Safety and tolerability of donepezil 23mg in moderate to severe Alzheimer's disease. Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A, BMC Neurol 2011 11 57
20. Dal Bianco P, Stähelin HB, Hartman R, Gharabawi M, on behalf of the B303 Exelon Study Group.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [published erratum appears in: BMJ. 2001;322:1456]. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, BMJ 1999 318 633 638
21. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG, Int J Geriatr Psychiatry 2004 19 624 633 (Pubitemid 38996839)